Search - tctmd.com

Displaying 261 - 280 of 315

Sort: Relevancy | Date

News Conference News EuroPCR 2012

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Caitlin E. Cox

May 22, 2012

News Conference News EuroPCR 2012

Trials Take on Permanent- vs. Biodegradable-Polymer Technology

Caitlin E. Cox

May 17, 2012

News Conference News EuroPCR 2012

CIBELES: Xience Stands Up to Cypher for CTO PCI

Caitlin E. Cox

May 17, 2012

News Conference News EuroPCR 2012

Biolimus-Eluting Stents Perform Well in STEMI, Unselected Populations

Jason Kahn

May 15, 2012

Presentation TCT Russia 2012

Lessons from Pooled Data with Xience Everolimus-Eluting Stents

Presenter: Gregg W. Stone

April 26, 2012

Presentation ACC 2012

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

Presenter: Gregg Stone

March 28, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Daily News

SES Effective for Both Focal, Diffuse DES Restenosis

March 13, 2012

News Daily News

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

March 13, 2012

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Jason Kahn

March 06, 2012

News Daily News

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

Jason Kahn

March 06, 2012

News Daily News

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Yael L. Maxwell

March 06, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

L.A. McKeown

February 20, 2012

Presentation

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

Presenter: C. Von Birgelen

February 20, 2012

News Daily News

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

January 24, 2012

News Daily News

SCAAR: Second-Generation DES Improve Hard Outcomes

Yael L. Maxwell

January 08, 2012

Presentation TCT 2012

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Presenter: David R. Rutledge, James B. Hermiller, Jin Wang, Mitchell W. Krucoff

January 03, 2012

Advertisement

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Trials Take on Permanent- vs. Biodegradable-Polymer Technology

CIBELES: Xience Stands Up to Cypher for CTO PCI

Biolimus-Eluting Stents Perform Well in STEMI, Unselected Populations

Lessons from Pooled Data with Xience Everolimus-Eluting Stents

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

SES Effective for Both Focal, Diffuse DES Restenosis

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

SCAAR: Second-Generation DES Improve Hard Outcomes

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content